An in vitro study on the metabolism and possible drug interactions of rokitamycln, a macrolide antibiotic, using human liver microsomes

Drug Metabolism and Disposition

Volumn 27, Issue 7, 1999, Pages 776-785

  Zhao, Xue Jun ^a,b   Koyama, Eriko ^a   Ishizaki, Takashi ^a,c  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIS NITRO PHENYLPHOSPHATE; CARBOXYLESTERASE; CHLORPHENIRAMINE; CHOLINESTERASE; CLARITHROMYCIN; DESIPRAMINE; DIPHENHYDRAMINE; DRUG; ERYTHROMYCIN; ESTERASE INHIBITOR; KITASAMYCIN DERIVATIVE; LEUCOMYCIN A7; LEUCOMYCIN V; MACROLIDE; MEQUITAZINE; PHYSOSTIGMINE; PROADIFEN; PROMETHAZINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; ROKITAMYCIN; TERFENADINE; THEOPHYLLINE; TRIAZOLAM; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG INTERACTION; DRUG METABOLISM; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CARBOHYDRATE SEQUENCE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; ISOENZYMES; MICROSOMES, LIVER; MIOCAMYCIN; MOLECULAR SEQUENCE DATA;

LETTUCE MOSAIC VIRUS;

EID: 0033060738     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Amsden GW (1995) Macrolides versus alalides: A drug interaction update. Ann Pharmacother 52:906-917.
2. Burnie J and Matthews R (1985) TMS-19Q. Drugs Future 10:486-489.
3. Cazzola M, Matera MG, Paterno E, Scaglione F, Santangelo G and Rossi F (1991) Impact of rokitamycin, a new 16-membered macrolide, on serum theophylline. J Chemother 3:240-244.
4. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T and Ishizaki T (1993) Oxidative metabolism of omeprazole in human liver microsomes: Cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 266:52-59.
5. Chiba K, Saitoh A, Koyama E, Tani M, Hayashi M and Ishizaki T (1994) The role of S-mephenytoin 4′-hydroxylase in imipramine metabolism by human liver microsomes: A two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br J Clin Pharmacol 37:237-242.
6. Dixon M and Webb EC (1964) Enzyme kinetics, in Enzymes (Dixon M and Webb EC eds) pp 5-166, Academic Press, New York.
7. Echizen H, Kawasaki H, Chiba K, Tani M and Ishizaki T (1993) A potent inhibition effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. J Pharmacol Exp Ther 264:1425-1431.
8. Gillum JG, Israel DS and Polk RE (1993) Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 25:450-482.
9. Goldstein JA and de Morais SMF (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285-299.
10. Goto S, Tsuji A, Ogawa M, Yokoyama S, Sagai H, Toriya M, Morohoshi T and Hayano K (1984) Bacteriological evaluations of the metabolites of TMS-19-Q, a new macrolide antibiotic. Chemotherapy 32(Suppl 6):37-45.
11. Guengerich FP (1994) Catalytic selectivity of human cytochrome P450 enzymes: Relevance to drug metabolism and toxicity. Toxicol Lett 70:133-138.
12. Guengerich FP, Müller-Enoch D and Blair IA (1986) Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 30:287-295.
13. Hara K (1987) Rokitamycin. Jpn J Antibiot 40:1851-1866.
14. Hosokawa M, Endo T, Fujisawa M, Hara S, Iwata N, Sato Y and Satoh T (1995) Interindividual variation in carboxylesterase levels in human liver microsomes. Drug Metab Dispos 23:1022-1027.
15. Iatsimirskaia E, Tulebaev S, Storozhuk E, Utkin I, Smith D, Gerber N and Koudriakova T (1997) Metabolism of rifabutin in human enterocyte and liver microsomes, and drug interactions with macrolides and antifungal agents. Clin Pharmacol Ther 61:554-562.
16. Ishizaki T, Baba T, Murabayashi S, Kubota K, Hara K and Kurimoto F (1988) Effect of cimetidine on the pharmacokinetics and pharmacodynamics of enalapril in normal volunteers. J Cardiovasc Pharmacol 12:512-519.
17. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver. Pharmacol Rev 50:387-411.
18. Kamendulis LM, Brzezinski MR, Pindel EV, Bosron WF and Dean RA (1996) Metabolism of cocaine and heroin if catalyzed by the same human liver carboxylesterases. J Pharmacol Exp Ther 279:713-717.
19. Kobayashi S, Murray S, Watson D, Sesardic D, Davies DS and Boobis AR (1989) The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine is the inverse of that in man. Biochem Pharmacol 38:2795-2799.
20. Kronbach T, Mathys D, Ueno M, Gonzalez FJ and Meyer US (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96.
21. Kunze KL and Trager WF (1993) Isoform-selective mechanism-based inhibition of human cytochrome P450 IA2 by furafylline. Chem Res Toxicol 6:649-656.
22. Leemann T, Transon C and Dayer P (1992) Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 52:29-34.
23. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
24. Marre F, de Sousa O, Roloff AM and Rahmani R (1993) In vitro interaction between cyclosporin and macrolide antibiotics. Br J Clin Pharmacol 35:447-448.
25. Morishita M, Ohno M, Serizawa K, Fujiwara T and Sakakibara H (1984a) Isolation and identification of metabolites of TMS-19-Q. Chemotherapy 32(Suppl 6):85-92.
26. Morishita M, Suzuki T and Hayano K (1987) The in vivo pharmacokinetics of rokitamycin: A new macrolide antibiotic. Chemother Field 3:381-390.
27. Morishita M, Suzuki T, Sakai A, Endo S, Watanabe M, Nagata A and Ishioka T (1984b) Studies on absorption, metabolism and excretion of TMS-19-Q in humans. Chemotherapy 32(Suppl 6):99-115.
28. 5). Chemotherapy 32(Suppl 6):12-25.
29. Newton DJ, Wang RW and Lu AYH (1995) Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
30. 1-receplor antagonists (the antihistamines). Clin Pharmacokinet 10:477-497.
31. Penston JG and McColl KEL (1997) Eradication of Helicobacter pylori: An objective assessment of current therapies. Br J Clin Pharmacol 43:223-243.
32. Periti P, Mazzei T, Mini E and Novelli A (1992) Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 23:106-131.
33. Robertson IGC and Bland TJ (1993) Inhibition by SKF-525A of the aldehyde oxidase-mediated metabolism of the experimental antitumour agent acridine carboxamide. Biochem Pharmacol 45:2159-2162.
34. Rodrigues AD, Roberts EM, Mulford DJ, Yao Y and Ouellet D (1997) Oxidative metabolism of clarithromycin in the presence of human liver microsomes: Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 25:623-630.
35. Rossi M, Markovitz S and Callahan T (1987) Defining the active site of cytochrome P-450: The crystal and molecular structure of an inhibitor, SKF-525A. Carcinogenesis 8:881-887.
36. Sakai A, Iwasaki M, Suzuki T, Morishita M and Muranishi S (1988) Studies on the metabolic fate of 14C-rokitamycin: Absorption, distribution, metabolism and excretion in infant rats. Jpn J Antibiot 41:797-808.
37. Somogyi A and Muirhead M (1987) Pharmacokinetic interaction of cimetidine. Clin Pharmacokinet 12:321-366.
38. Sorkin EM and Heel RC (1985) Terfenadine: A review of its pharmacodynamic properties and therapeutic efficacy. Drugs 29:34-56.
39. Stoddart AM and Levine WG (1992) Azoreductase activity by purified rabbit liver aldehyde oxidase. Biochem Pharmacol 43:2227-2235.
40. Suzuki T, Sakai A, Morishita M and Muranishi S (1987a) Studies on the metabolic fate of 14C-rokitamycin. IV. Absorption, metabolism and excretion in dogs. Jpn J Antibiot 40:539-552.
41. Suzuki T, Sakai A, Morishita M and Muranishi S (1987b) Studies on the metabolic fate of 14C-rokitamycin. I. Absorption, distribution, metabolism and excretion in rats. Jpn J Antibiot 40:499-518.
42. Tassaneeyakul W, Birkett DJ, Veronese ME, Mcmanus ME, Tukey RH, Quattrochi LC, Gelboin HV and Miners JO (1993a) Specificity of substrate and inhibitor probes for human cytochrome P45C1A1 and 1A2. J Pharmacol Exp Ther 265:401-407.
43. Tassaneeyakul W, Veronese ME, Birkett DJ, Gonzalez FJ and Miners JO (1993b) Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem Pharmacol 46:1751-1981.
44. Tunek A and Svensson L-Å (1988) Bambuterol, a carbamate ester prodrug of terbutaline, as inhibitor of cholinesterases in human blood. Drug Metab Dispos 16:759-764.
45. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS and Shader RI (1994) Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinine and ketoconazole: A model system to predict drug interactions in vivo. J Pharmacol Exp Ther 268:1278-1283.
46. von Rosentiel N-A and Adam D (1995) Macrolide antibacterials: Drug interactions of clinical significance. Drug Safety 13:105-122.
47. Walsh JH and Peterson WL (1995) The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 333:984-991.
48. Watkins PB, Wrighton SA, Maurel JP, Schuetz EG, Mendez-Picon G, Parker GA and Guzelian PS (1985) Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci USA 82:6310-6314.
49. Williams FM (1985) Clinical significance of esterases in man. Clin Pharmacokinet 10:392-403.
50. Wrighton SA and Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21.
51. Yamaoka K, Tanigara Y, Nakagawa T and Uno J (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobiodyn 4:879-885.
52. Yasumori T, Murayama N, Yamazoe Y and Kato R (1990) Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2. Clin Pharmacol Ther 47:313-322.
53. Yoshihara S and Tatsumi K (1985) Guinea pig liver aldehyde oxidase as a sulfoxide reductase: Its purification and characterization. Arch Biochem Biophys 242:213-224.
54. Zhao XJ and Ishizaki T (1997a) The in vitro hepatic metabolism of quinine in mice, rats and dogs: Comparison with human liver microsomes. J Pharmacol Exp Ther 283:1168-1176.
55. Zhao XJ and Ishizaki T (1997b) Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. Br J Clin Pharmacol 44:505-511.
56. Zhao XJ, Yokoyama H, Chiba K, Wanwimolruk S and Ishizaki T (1996) Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human liver microsomes and nine recombinant human cytochromes P450. J Pharmacol Exp Ther 279: 1327-1334.